WASHINGTON (AP) — The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies to win approval of new drugs, the latest change from Trump administration ...

Logan Paul breaks world record as Pokémon card sells for $16.5 million Australia are on the brink of a humiliating World Cup exit. They deserve it 'Unconscionable': Westpac lashed by judge after ...

Regular family dinners have long been credited with a range of positive outcomes—including, just for starters, better parent-teen relationships, reduced stress, a healthier overall diet for ...

Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...

A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the ...

A study by the financial firm Jefferies highlights a surprising perk for carriers: lower fuel costs as slimmer passengers lighten their aircraft’s loads. By Gabe Castro-Root Weight-loss drugs like ...

Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's ‌new fast-track program after agency scientists flagged safety and ...

Both companies now aim to win in the oral weight loss drug market. The companies make GLP-1 drugs, products that interact with hormonal pathways involved in the digestion process -- and these types of ...

At this point, millions of people in the U.S. have tried at least one of a variety of glucagonlike peptide 1 (GLP-1) receptor agonist drugs such as Zepbound or Wegovy. For some, these medications have ...

People who stop taking GLP-1 drugs such as Ozempic and Wegovy for weight loss are projected to regain their shed pounds within about 1½ years, a review of existing research has found. The paper also ...

A good night's sleep might be an additional benefit some gain from taking weight-loss drugs like Ozempic and Zepbound, a new study says. Obese patients with type 2 diabetes are less likely to need a ...

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, ...